Stock Performance and Market Context
On 14 July 2026, Fredun Pharmaceuticals Ltd’s stock price soared to an intraday high of Rs.2950, representing a 7.13% increase on the day and a 3.13% gain compared to the previous close. This performance outpaced the Pharmaceuticals & Biotechnology sector by 2.83% and the broader Sensex index, which declined by 0.36% on the same day. The stock has been on a positive trajectory, gaining for two consecutive days and delivering a cumulative return of 9.55% during this period.
Fredun Pharmaceuticals is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend. The overall technical outlook remains positive, with indicators such as MACD, KST, and Bollinger Bands showing bullish momentum on both weekly and monthly timeframes.
Long-Term Returns and Relative Strength
The stock’s long-term performance has been exceptional. Over the past year, Fredun Pharmaceuticals has delivered a staggering 216.21% return, vastly outperforming the Sensex’s negative 5.98% return in the same period. Year-to-date, the stock has gained 79.43%, while the Sensex has declined by 9.25%. Over three years, the company’s shares have appreciated by 257.35%, compared to the Sensex’s 17.07% gain. The five-year return stands at an impressive 560.83%, and over a decade, the stock has surged by an extraordinary 11,228.00%, highlighting its sustained growth trajectory.
Financial Growth and Profitability Metrics
Fredun Pharmaceuticals has demonstrated healthy long-term growth, with net sales increasing at an annual compound growth rate of 36.42% and operating profit growing at 59.04% over five years. The company has reported positive results for eight consecutive quarters, reflecting consistent operational strength.
Key quarterly financial highlights include a Profit Before Tax (excluding other income) of Rs.11.25 crores, which has grown by 54.96%, and a highest-ever Profit After Tax of Rs.10.78 crores. The company’s operating cash flow for the year reached a peak of Rs.16.44 crores, underscoring strong cash generation capabilities.
Valuation and Quality Assessment
Fredun Pharmaceuticals currently trades at a price-to-earnings ratio of 40x (TTM) and a price-to-book value of 5.42x. Its enterprise value to capital employed ratio stands at a modest 3.83x, indicating an attractive valuation relative to its capital base. The company’s PEG ratio is 0.70, suggesting that its price growth is favourable compared to earnings growth.
Dividend metrics show a modest yield of 0.05%, with a recent dividend payout of Rs.0.7 per share and a payout ratio of 1.15%. The ex-dividend date was 23 June 2026.
Quality assessments rate the company as average overall, with excellent growth but below-average capital structure. The company maintains moderate leverage, with an average debt to EBITDA ratio of 2.93 and net debt to equity of 0.56. Return on capital employed (ROCE) is strong at 19.9%, while return on equity (ROE) is relatively weaker at 12.48%. Importantly, there is no promoter share pledging, and institutional holdings remain low at 3.89%.
Promoter Confidence and Shareholding
Promoter confidence in Fredun Pharmaceuticals remains robust, as evidenced by an increase in promoter stake by 1.11% over the previous quarter. Currently, promoters hold 44.17% of the company’s shares, signalling a strong commitment to the business and its prospects.
Short-Term Financial Trends
Recent quarterly data highlights continued positive momentum. Net sales reached a quarterly high of Rs.213.05 crores, while profit before depreciation, interest, and tax (Pbdit) hit Rs.28.88 crores. The company’s debt-equity ratio improved to a low of 0.80 times in the half-year period ending March 2026. Despite a relatively high interest expense of Rs.14.49 crores in the quarter, operating profit to interest coverage remains at a minimum of 1.99 times, reflecting manageable interest obligations.
Trading Volumes and Market Activity
Delivery volumes have shown a notable increase, with a 1-day delivery change of 197.88% compared to the 5-day average and a 1-month delivery change of 6.01%. On 13 July 2026, the stock recorded a delivery volume of 12.31 thousand shares, accounting for 82.13% of total volume, well above the trailing one-month average of 7.96 thousand shares.
Summary of Key Technical Levels
The stock’s immediate support level is at Rs.866.05, corresponding to its 52-week low, while immediate resistance was recently surpassed at Rs.2,620.85 (20-day moving average). Major resistance levels at Rs.2,116.13 (100-day moving average) and Rs.1,861.46 (200-day moving average) have been decisively breached, reinforcing the bullish trend. The new 52-week high of Rs.2,950 represents a far resistance level now established as the stock’s peak.
Conclusion
Fredun Pharmaceuticals Ltd’s attainment of an all-time high price of Rs.2950 on 14 July 2026 marks a significant milestone in its market journey. Supported by strong financial growth, consistent profitability, attractive valuation metrics, and rising promoter confidence, the company has demonstrated resilience and strength within the Pharmaceuticals & Biotechnology sector. Its sustained outperformance relative to benchmark indices and peers underscores the robustness of its business model and operational execution.
